Author

M. Rogava

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

B. Izar· 2 shared C. R. Ager· 2 shared J. C. Melms· 2 shared A. D. Amin· 1 shared A. Obradovic· 1 shared B. T. Fullerton· 1 shared C. Bernatchez· 1 shared C. G. Drake· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. Izar

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

C. R. Ager, M. Zhang, M. Chaimowitz, S. Bansal, A. Obradovic, M. Rogava, J. C. Melms, P. McCann, C. Spina, C. G. Drake, M. C. Dallos, B. Izar

The paper identifies KLRG1-expressing CD4 T cell subsets linked to tumor progression and immunotherapy response using longitudinal flow cytometry and machine learning.

bioRxiv · Jan 1, 2023Immunology

The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity

P. Ho, J. C. Melms, M. Rogava, C. J. Frangieh, S. B. Shah, Z. Walsh, O. Kyrysyuk, A. D. Amin, L. Caprio, B. T. Fullerton, R. Soni, C. R. Ager, J. Biermann, Y. Wang, M. Mu, , B. Izar

The paper identifies the CD58:CD2 axis as co-regulated with PD-L1 via CMTM6 and shows its role in anti-tumor immunity, proposing therapeutic strategies to enhance immunotherapy.

bioRxiv · Mar 21, 2022 · PreprintCancer Biology